Press Releases

ROCKVILLE, Md. , March 15, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today the pricing of its private
Posted: March 15, 2018
ROCKVILLE, Md. , March 13, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) (the "Company"), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced today that, subject to market and
Posted: March 13, 2018
Fourth quarter 2017 total revenue of $88.4 million , a 42% increase over 2016, and fourth quarter 2017 net product sales of $86.3 million , a 41% increase over 2016. Fourth quarter 2017 operating earnings of $34.3 million , a 110% increase over 2016. Full year 2017 total revenue of $302.2 million ,
Posted: February 27, 2018
Displaying 11 - 20 of 20